Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date

被引：26
|
作者：
Montemorano, Lauren [1 ]
Lightfoot, Michelle D. S. [2 ]
Bixel, Kristin [2 ]
机构：
[1] Ohio State Univ, Dept Obstet & Gynecol, Wexner Med Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, James Canc Hosp, Dept Obstet & Gynecol,Div Gynecol Oncol, Columbus, OH 43210 USA
来源：
ONCOTARGETS AND THERAPY | 2019年 / 12卷
关键词：
olaparib; PARP inhibitor; ovarian cancer; maintenance; DOUBLE-BLIND; THERAPY; CHEMOTHERAPY; BEVACIZUMAB; INHIBITORS; CARCINOMA;
D O I：
10.2147/OTT.S195552
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
PARP inhibitors have shown significant promise in the treatment of ovarian cancer. Olaparib is a PARP inhibitor that has been approved for maintenance for BRCA-mutated ovarian cancer in the recurrent and front-line setting as well as for treatment of BRCA-mutated ovarian cancer in patients who have received multiple prior lines of chemotherapy. In this review, we focus on the use of olaparib in the maintenance setting including the evidence to date, ongoing research, and future directions.
引用
收藏
页码：11497 / 11506
页数：10
相关论文
共 50 条
  • [21] Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
    Labidi-Galy, S. Intidhar
    Rouge, Thibault de La Motte
    Derbel, Olfa
    Wolfer, Anita
    Kalbacher, Elsa
    Olivier, Timothee
    Combes, Jean-Damien
    Heimgartner-Hu, Ketty
    Tredan, Olivier
    Guevara, Hemerson
    Heudel, Pierre-Etienne
    Reverdy, Thibaut
    Bazan, Fernando
    Heinzelmann-Schwarz, Viola
    Fehr, Mathias
    de Castelbajac, Victoire
    Vaflard, Pauline
    Crivelli, Louise
    Bonadona, Valerie
    Viassolo, Valeria
    Buisson, Adrien
    Golmard, Lisa
    Rodrigues, Manuel
    Ray-Coquard, Isabelle
    GYNECOLOGIC ONCOLOGY, 2019, 155 (02) : 262 - 269
  • [22] Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
    Shu, Yamin
    Liu, Yanxin
    He, Xucheng
    Ding, Yufeng
    Zhang, Qilin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [23] Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome
    Cecere, Sabrina Chiara
    Giannone, Gaia
    Salutari, Vanda
    Arenare, Laura
    Lorusso, Domenica
    Ronzino, Graziana
    Lauria, Rossella
    Cormio, Gennaro
    Carella, Claudia
    Scollo, Paolo
    Ghizzoni, Viola
    Raspagliesi, Francesco
    Di Napoli, Marilena
    Mazzoni, Enrica
    Marchetti, Claudia
    Bergamini, Alice
    Orditura, Michele
    Valabrega, Giorgio
    Scambia, Giovanni
    Maltese, Giuseppa
    De Matteis, Elisabetta
    Cardalesi, Cinzia
    Loizzi, Vera
    Boccia, Serena
    Naglieri, Emanuele
    Scandurra, Giuseppa
    Pignata, Sandro
    GYNECOLOGIC ONCOLOGY, 2020, 156 (01) : 38 - 44
  • [24] Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation
    Stewart, James
    George, Angela
    Banerjee, Susana
    EXPERT REVIEW OF ANTICANCER THERAPY, 2018, 18 (10) : 947 - 958
  • [25] Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice
    Romero, Ignacio
    Guerra, Eva
    Madariaga, Ainhoa
    Manso, Luis
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [26] An update on the safety of olaparib for treating ovarian cancer
    Cottrell, Kelsi
    Clark, Caroline L.
    Penson, Richard T.
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (04) : 447 - 451
  • [27] Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer
    Moss, Haley A.
    Perhanidis, Jessica A.
    Havrilesky, Laura J.
    Secord, Angeles Alvarez
    GYNECOLOGIC ONCOLOGY, 2021, 163 (01) : 50 - 56
  • [28] Maintenance Therapy in the Treatment of Recurrent Epithelial Ovarian Cancer
    Gnade, Colette
    Mcdonald, Megan E.
    CLINICAL OBSTETRICS AND GYNECOLOGY, 2020, 63 (01) : 86 - 91
  • [29] Profile of olaparib in the treatment of advanced ovarian cancer
    Chase, Dana M.
    Patel, Shreya
    Shields, Kristin
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2016, 8 : 125 - 129
  • [30] Olaparib in the management of ovarian cancer
    Bixel, Kristin
    Hays, John L.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2015, 8 : 127 - 135
12345